Dasatinib is Used for treating protein tyrosine kinase-associated disorders and various types of cancer, including chronic myelogenous leukemia. It was first introduced by Bristol Myers Squibb Co in its drug Sprycel on Jun 28, 2006. Another drug containing Dasatinib is Phyrago. 3 different companies have introduced drugs containing Dasatinib.

Dasatinib Patents

Given below is the list of patents protecting Dasatinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Phyrago	US11202778	Amorphous solid dispersions of dasatinib and uses thereof	Jan 22, 2041	Nanocopoeia
Phyrago	US11298356	Amorphous solid dispersions of dasatinib and uses thereof	Jan 22, 2041	Nanocopoeia
Phyrago	US11324745	Amorphous solid dispersions of dasatinib and uses thereof	Jan 22, 2041	Nanocopoeia
Sprycel	US6596746	Cyclic protein tyrosine kinase inhibitors	Jun 28, 2020 (Expired)	Bristol Myers Squibb
Sprycel	US6596746 (Pediatric)	Cyclic protein tyrosine kinase inhibitors	Dec 28, 2020 (Expired)	Bristol Myers Squibb
Sprycel	US7125875	Cyclic protein tyrosine kinase inhibitors	Apr 13, 2020 (Expired)	Bristol Myers Squibb
Sprycel	US7125875 (Pediatric)	Cyclic protein tyrosine kinase inhibitors	Oct 13, 2020 (Expired)	Bristol Myers Squibb
Sprycel	US7153856	Cyclic protein tyrosine kinase inhibitors	Apr 28, 2020 (Expired)	Bristol Myers Squibb
Sprycel	US7153856 (Pediatric)	Cyclic protein tyrosine kinase inhibitors	Oct 28, 2020 (Expired)	Bristol Myers Squibb
Sprycel	US7491725	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Mar 28, 2026	Bristol Myers Squibb
Sprycel	US7491725 (Pediatric)	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Sep 28, 2026	Bristol Myers Squibb
Sprycel	US8680103	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Feb 04, 2025	Bristol Myers Squibb
Sprycel	US8680103 (Pediatric)	Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors	Aug 04, 2025	Bristol Myers Squibb

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasatinib's patents.

Latest Legal Activities on Dasatinib's Patents

Given below is the list recent legal activities going on the following patents of Dasatinib.

Event	Date	Patent/Publication
Today's Legal Activities
Payment of Maintenance Fee, 12th Year, Large Entity	06 Aug, 2020	US7491725
Payment of Maintenance Fee, 12th Year, Large Entity	14 Jun, 2018	US7153856(Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity	12 Apr, 2018	US7125875
Post Issue Communication - Certificate of Correction	22 Nov, 2011	US7491725
Email Notification	03 Aug, 2010	US7491725
Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Allowance	28 Jul, 2010	US7491725
Record a Petition Decision of Granted for Patent Term Adjustment after Allowance	27 Jul, 2010	US7491725
Adjustment of PTA Calculation by PTO	27 Jul, 2010	US7491725
Court Processing Terminated	23 Jun, 2010	US7491725
Decision in Civil Action - Dismissed by Court	23 Jun, 2010	US7491725

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳